<DOC>
	<DOCNO>NCT00084838</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Giving one chemotherapy drug radiation therapy may kill tumor cell . PURPOSE : This phase II trial study well give intrathecal systemic combination chemotherapy together radiation therapy work treat young patient newly diagnose central nervous system ( CNS ) atypical teratoid/rhabdoid tumor .</brief_summary>
	<brief_title>Chemotherapy Combined With Radiation Therapy Newly Diagnosed CNS AT/RT</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine efficacy intensive systemic intrathecal chemotherapy radiotherapy , term medial survival , child newly diagnose central nervous system atypical teratoid/rhabdoid tumor comparison historical outcome prior trial . Secondary - Determine toxicity profile tolerability regimen patient . - Determine chemosensitivity patient ' tumor Magnetic Resonance Imaging ( MRI ) attempt maximum surgical resection 2 course regimen . - Determine predictive value INI-1 gene mutation determine prognosis compare tumor sample patient vs without mutation treat regimen . STATISTICAL DESIGN : This single arm design evaluate median overall survival . The chosen historical control estimate 7 month base 2 large multi-institutional study similar set alternative 20.5 month base DFCI pilot study . There 90 % power detect improvement assume 1-sided 0.10 alpha 17 eligible patient . Sample size ( n=20 patient ) inflate expect 10-15 % ineligible rate . TREATMENT : Induction chemotherapy require initiate within 50 day definitive surgery . - Central Nervous System ( CNS ) /intrathecal therapy : All patient M0 disease receive triple intrathecal ( IT ) chemotherapy comprise methotrexate ( MTX ) , cytarabine , hydrocortisone day 1 week 1 , 2 , 4 , 7 , 13 , 19 , 27 , 33 , 39 , 45 , 51 follow oral intravenous ( IV ) leucovorin calcium give 24 hour MTX dose . Patients initially positive cerebrospinal fluid ( CSF ) cytology ( M+ ) receive triple IT chemotherapy weekly 2 consecutive CSF sample negative malignant cell . - Pre-irradiation induction therapy ( week 1-6 ) : Patients receive vincristine IV day 1 week 1-6 ; cisplatin IV 8 hour day 1 doxorubicin IV continuously 48 hour begin day 2 week 1 4 ; cyclophosphamide IV continuously 72 hour begin day 2 week 1 ; etoposide IV 1 hour day 1-3 week 4 ; filgrastim ( G-CSF ) subcutaneously ( SC ) begin day 6 week 1 day 4 week 4 continue blood count recover . - Induction chemoradiotherapy ( week 7-12 ) : Patients receive vincristine IV day 1 week 7-12 ; cisplatin IV 8 hour day 1 , cyclophosphamide IV 1 hour day 2 , etoposide IV 1 hour day 1-3 week 7 10 ; granulocyte-colony stimulating factor ( G-CSF ) subcutaneous ( SC ) daily begin day 4 week 7 10 continue blood count recover . Patients M0 disease patient 3 year age M+ disease undergo radiotherapy primary tumor daily week 7-12 . Patients 3 year age M+ disease undergo craniospinal irradiation ( CSI ) daily week 7-12 negative cerebral spinal fluid ( CSF ) cytology achieve . - Post-radiation induction therapy ( week 13-18 ) : Patients receive vincristine IV day 1 week 13 16 ; doxorubicin cyclophosphamide pre-irradiation induction therapy begin day 1 week 13 ; cyclophosphamide IV 1 hour day 1-3 week 16 ; dactinomycin IV day 1-5 week 16 ; G-CSF SC daily begin day 6 week 13 16 continue blood count recover . - Maintenance chemotherapy ( week 19-42 ) : Patients receive vincristine IV day 1 week 27 , 33 , 39 day 1 5 week 30 , 36 , 42 ; doxorubicin cyclophosphamide pre-irradiation induction begin day 1 week 27 33 ; doxorubicin IV 15 minute dexrazoxane ( DX ) IV 15 minute day 1 2 week 39 ; cyclophosphamide IV 1 hour day 1-3 week 30 , 36 , 39 , 42 ; dactinomycin IV day 1-5 week 30 , 36 , 42 day 1 week 19 23 ; oral temozolomide day 1-5 week 19 23 ; G-CSF SC daily begin day 6 week 19 , 23 , 30 , 36 , 42 , day 5 week 27 33 , day 4 week 39 continue blood count recover . - Doxorubicin continuation therapy ( patient receive CSI mediastinal radiotherapy ) ( week 45-51 ) : Patients receive vincristine IV day 1 week 45 , 48 , 51 day 5 week 48 ; doxorubicin IV 15 minute DX IV 15 minute day 1 2 week 45 51 ; cyclophosphamide IV 1 hour day 1-3 week 45 , 48 , 51 ; dactinomycin IV day 1-5 week 48 ; G-CSF SC daily begin day 4 week 45 51 day 6 week 48 continue blood count recover . - Non-doxorubicin continuation therapy ( patient receive CSI mediastinal radiotherapy ) ( week 45-51 ) : Patients receive cyclophosphamide G-CSF doxorubicin continuation therapy ; vincristine IV day 1 5 week 45 , 48 , 51 ; dactinomycin IV day 1-5 week 45 , 48 , 51 . Treatment continue absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Rhabdoid Tumor</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Dexrazoxane</mesh_term>
	<mesh_term>Razoxane</mesh_term>
	<mesh_term>Dactinomycin</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary intracranial Central Nervous System ( CNS ) atypical teratoid/rhabdoid tumor OR Tumor tissue possess INI1 gene mutation No metastases disseminate outside CNS abdominal chest computer tomography ( CT ) scan , kidney imaging , bone marrow biopsy No obstruction cerebrospinal fluid ( CSF ) flow CSF flow study Definitive surgical resection tumor within past 35 day PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 50100 % OR Lansky 50100 % Life expectancy Not specify Hematopoietic Hemoglobin &gt; 10 g/dL Absolute neutrophil count &gt; 1,000/mm^3 Platelet count &gt; 100,000/mm^3 Hepatic Bilirubin ≤ 1.5 mg/dL SGPT &lt; 10 time normal Renal Creatinine ≤ 1.5 time normal Other Willing placement central venous access line PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy Endocrine therapy Prior steroid allow Radiotherapy No prior radiotherapy Surgery See Disease Characteristics Other No prior concurrent investigational agent Concurrent anticonvulsant agent allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>childhood atypical teratoid/rhabdoid tumor</keyword>
</DOC>